Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Lilly and Hanmi forge $690 million autoimmune pact; Lilly cited significant unmet medical need in many prevalent autoimmune diseases where individual patient…
Lilly characterized the interim Phase 2 result bluntly: 'the difference between the placebo and active treatment arms of the study was not sufficient enough to…
Coverage noted Lilly's decision left HM71224 chasing alternative indications (lupus, lupus nephritis, Sjogren's) in a category where AbbVie/Janssen's Imbruvica…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Lilly and Hanmi entered an exclusive worldwide (excluding China, Hong Kong, Korea) license and collaboration for HM71224, an oral BTK inhibitor for autoimmune diseases. Hanmi received $50M upfront with up to $640M in development, regulatory, and sales milestones plus tiered double-digit royalties. Lilly terminated the deal in 2019 after Phase 2 RA trial failed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Hanmi Pharmaceutical Co., Ltd. (HM71224 program) (this deal) | 2015 | $690M | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2015 deals · Eli Lilly and Company deals · Immunology deals